ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-Linzagolix for uterine fibroids: Received c onfirmation of p ositive CHMP opinion for marketing authorization application ; United States NDA PDUFA date in Q3:22 -

ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update

GENEVA, Switzerland May 1 6 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright Global Investment Conference, taking place virtually and in Miami, Florida from May 23 – 26, 2022.

ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference

BGC Partners

B2Gold

Safe Bulkers

Telefonica SA

United Wholesale Mortgage

Penny stocks carry considerable risk, but they can also generate life-changing returns. Here are some to consider buying today.

What Are the Top 7 Penny Stocks? And Should You Buy?

GENEVA, Switzerland – May 1 2 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it plans to host a conference call on Tuesday, May 17, 2022, at 8:00 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update.

ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

- Additional data from the PRIMROSE Phase 3 stud ies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15 am PT/12:15 pm ET-

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer

Gamida Cell Ltd

Imperial Petroleum

Jiuzi Holdings

Redbox Entertainment

Why are these penny stocks moving in the stock market today? The post 5 Hot Penny Stocks To Watch With Premarket Momentum & News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Hot Penny Stocks To Watch With Premarket Momentum & News

ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

ObsEva Annual General Meeting 2022

ObsEva Annual Report 2021

-Reductions in dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP), the co-primary efficacy endpoints, compared to placebo were observed for both doses after 1 and 2 months of treatment, respectively, and these reductions increased up to 6 months-

ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

-Linzagolix for uterine fibroids: US NDA Q3:22 PDUFA date; Positive CHMP opinion-

ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update

- Partnership leverages Theramex's leading women's health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix across global markets outside of the U.S., Canada and Asia -

ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix

ObsEva SA  OBSV said that based on ongoing communications with the European Medicines Agency (EMA), it expects further questions on the linzagolix application, thereby extending the application timeline.  Get the Inside Access Traders Are Using to Profit More and Win Bigger.

ObsEva Expects Delay In Linzagolix Application Submission In Europe For Uterine Fibroids

ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Bakkt Holdings

Spire Global

What to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for February 1st, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for February 1st, 2022

The stock price of Obseva SA (NASDAQ: OBSV) increased by over 15% pre-market today. This is why it happened.

Obseva (OBSV) Stock: Why The Price Surged Up Today

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

ObsEva Appoints Katja Buhrer as Chief Strategy Officer

BTCS

Cronos Group

Hive Blockchain Technologies Ltd

Hecla Mining

Transocean

Electrameccanica

These penny stocks look poised for a rally in January 2022 and can possibly deliver multi-fold returns in the next 12 months. The post 7 Penny Stocks to Buy for January appeared first on InvestorPlace.

7 Penny Stocks to Buy for January

-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months-

ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

GENEVA, Switzerland January 3 , 202 2 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright BioConnect Conference, to be held January 10-13, 2022.

ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference

BIOLASE

Clearside Biomedical

Calyxt

CohBar

Predictive Oncology Inc

Vista Gold

Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.

7 of the Best Penny Stocks Under $3 for 2022 to Buy Now

GENEVA, Switzerland December 20 , 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021.

ObsEva Added to the NASDAQ Biotechnology Index

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval for ObsEva SA's (NASDAQ: OBSV) linzagolix, an oral GnRH antagonist to manage moderate to severe symptoms of uterine fibroids. If approved, linzagolix would be the first and only approved GnRH receptor antagonist with a non-hormonal option to address the needs of women who cannot or do not want to take hormones.

Why Are ObsEva Shares Trading Higher Today?

- European Commission Decision Anticipated in Q1 2022-

ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

News for ObsEva Stock (OBSV)